Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nasal provocation test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Nasal provocation test. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-001088-11 Sponsor Protocol Number: s56489 Start Date*: 2014-07-29
    Sponsor Name:MEDA
    Full Title: Academic study on the effects of MP 29-02 nasal spray on inflammatory mediators in allergic rhinitis
    Medical condition: Allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000215-31 Sponsor Protocol Number: S65796 Start Date*: 2022-05-24
    Sponsor Name:UZ Leuven
    Full Title: A monocentric academic trial comparing the diagnostic value of history taking and nasal lysine aspirin provocation test in the diagnosis of AERD in CRSwNP patients
    Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic RhinoSinusitis with Nasal Polyps (CRSwNP)
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004855 10075084 Aspirin-exacerbated respiratory disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004889-18 Sponsor Protocol Number: 1.3 Start Date*: 2022-04-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab in patients with aspirin-exacerbated respiratory disease (AERD) -A single-center prospective pilot study
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad or Widal's triad, comprises the triad of allergic asthma, chronic rhinosinusitis with nasal polyps (CRswNP) and nonstero...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005079-21 Sponsor Protocol Number: LOTAB_2b_HDM Start Date*: 2018-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Alle...
    Medical condition: Patients Suffering from Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001611-50 Sponsor Protocol Number: S67072 Start Date*: 2022-11-15
    Sponsor Name:UZ Leuven
    Full Title: Patient reported efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease
    Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004855 10075084 Aspirin-exacerbated respiratory disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004830-32 Sponsor Protocol Number: ICPCT-2011-UA-FF Start Date*: 2012-01-27
    Sponsor Name:FAES FARMA, S.A.
    Full Title: Effects of bilastine on nasal volume after allergen-induced rhinitis in patients with allergic rhinitis
    Medical condition: Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003119-21 Sponsor Protocol Number: 1 Start Date*: 2017-12-22
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Omalizumab in patients with Aspirin-Exazerbated Respiratory Disease (AERD)
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or Widal's triad, comprises the triad of Asthma, chronic rhinosinusitis with nasal polyps (CRwNP) and nonsteroidal anti-...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000597-29 Sponsor Protocol Number: 2017-02-CHRMT Start Date*: 2021-06-02
    Sponsor Name:Centre Hospitalier Régional Metz-Thionville
    Full Title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
    Medical condition: mite allergenic rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002944-18 Sponsor Protocol Number: BIA-HDMP-201 Start Date*: 2016-11-14
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC R...
    Medical condition: The disease under study is allergic rhinoconjunctivitis secondary to sensitization to DPT and DF. Included in the study are patients diagnosed with that disease who also have associated mild asthma...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016815-39 Sponsor Protocol Number: il-ASIT1 Start Date*: 2010-01-15
    Sponsor Name:Allergy Unit Department of Oto-rhino-Laryngology Lund/Malmö University Hospital
    Full Title: Is Intralymphatic Allergen Immunotherapy effective and safe: A human randomized clinical trial
    Medical condition: Seasonal Allergic rhinitis due to pollen from grass and betula verrucosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005420-17 Sponsor Protocol Number: CC10-200601 Start Date*: 2007-01-23
    Sponsor Name:LTB4 Sweden AB
    Full Title: A double-blind, randomised, placebo-controlled, crossover, allergen challenge study, evaluating the safety, tolerability and effects of intranasal administration of recombinant human Clara Cell 10 ...
    Medical condition: The study is a proof-of-concept study with the objective to investigate whether rhCC10, administered intranasally, can affect the response to an allergen provocation test in subjects with allergic ...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004214-96 Sponsor Protocol Number: MEIN/15/Bil-PSR/002 Start Date*: 2017-02-02
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA
    Full Title: Bilastine and inflammation: an explorative study in subjects affected by Parietaria J.-induced Rhinoconjunctivitis – The Bi-FLO study
    Medical condition: Rhinoconjunctivitis induced by Parietaria J.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003067-31 Sponsor Protocol Number: 600-PG-PSC-156 Start Date*: 2006-09-25
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree pollen
    Medical condition: Rhinitis and/or rhinoconjunctivitis with or without allergic asthma caused by clinical relevant sensitization against tree pollen.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001259-63 Sponsor Protocol Number: Pollenvaccine2014-01-15 Start Date*: 2016-03-09
    Sponsor Name:Department of Clinical Science, Intervention and Technology, Karolinska Institute
    Full Title: Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial
    Medical condition: Patients with severe to moderate Allegic rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002317-10 Sponsor Protocol Number: SC-31A Start Date*: 2019-04-17
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000683-27 Sponsor Protocol Number: GRAY09 Start Date*: 2006-05-17
    Sponsor Name:Research and Innovation Services
    Full Title: A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients with Intermittent and Persistent Allergic Rhinitis
    Medical condition: Allergic Rhinitis - Both Persistent and Intermittent
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002805-21 Sponsor Protocol Number: D2530C00011 Start Date*: 2005-09-25
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal aller...
    Medical condition: This is a Phase II trial (Proof of Principle) in volunteer rhinitis subjects utilising a seasonal model of rhinitis and challenge agent
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003879-49 Sponsor Protocol Number: AB0802 Start Date*: 2009-03-27
    Sponsor Name:Artu Biologicals Europe B.V.
    Full Title: A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust ...
    Medical condition: Treatment of house dust mite induced allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005038-53 Sponsor Protocol Number: FIM-PRU-2018-01 Start Date*: 2019-05-16
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP w...
    Medical condition: LTP syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011999-30 Sponsor Protocol Number: VO64.08 Start Date*: 2009-09-16
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets on...
    Medical condition: House Dust Mite Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) DE (Prematurely Ended) FR (Completed) DK (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 07:47:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA